Evidence map›Paper›PMID 39256561›Full record

ArticleThe EMBO journal2024

The fitness cost of spurious phosphorylation.

David Bradley, Alexander Hogrebe, Rohan Dandage, Alexandre K Dubé, Mario Leutert, Ugo Dionne, Alexis Chang, Judit Villén, Christian R Landry

Abstract read
In one paragraph

Article in The EMBO journal, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. An AI-Ready Phosphorylation Meta-Analysis forJournal of proteome research · 2026
    Pooled it
  2. Article
  3. Carafe2 enables high qualitybioRxiv : the preprint server for biology · 2026
    Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors.

David Bradley *Institut de Biologie Intégrative et des Systèmes (IBIS), Université Laval, Québec, QC, Canada.ORCID https://orcid.org/0000-0002-5530-1789
Alexander Hogrebe *Department of Genome Sciences, University of Washington, Seattle, WA, USA.ORCID http://orcid.org/0000-0002-0203-6803
Rohan DandageInstitut de Biologie Intégrative et des Systèmes (IBIS), Université Laval, Québec, QC, Canada.ORCID http://orcid.org/0000-0002-6421-2067
Alexandre K DubéInstitut de Biologie Intégrative et des Systèmes (IBIS), Université Laval, Québec, QC, Canada.
Mario LeutertDepartment of Genome Sciences, University of Washington, Seattle, WA, USA.ORCID http://orcid.org/0000-0001-7921-4017
Ugo DionneInstitut de Biologie Intégrative et des Systèmes (IBIS), Université Laval, Québec, QC, Canada.
Alexis ChangDepartment of Genome Sciences, University of Washington, Seattle, WA, USA.
Judit VillénDepartment of Genome Sciences, University of Washington, Seattle, WA, USA. jvillen@uw.edu.ORCID http://orcid.org/0000-0002-1005-1739
Christian R LandryInstitut de Biologie Intégrative et des Systèmes (IBIS), Université Laval, Québec, QC, Canada. christian.landry@bio.ulaval.ca.ORCID http://orcid.org/0000-0003-3028-6866

Funding

INTERDISCIPLINARY TRAINING IN GENOMIC SCIENCEST32HG000035 · NHGRI · UNIVERSITY OF WASHINGTON · PI Bruce Colston Trapnell · 1995 to 2026
$24.2M
Emergent properties of signaling network degradation that mediate homeostatic failure during agingR01AG056359 · NIA · UNIVERSITY OF WASHINGTON · PI KAEBERLEIN, MATT, VILLEN, JUDIT · 2017 to 2021
$2.9M
Towards a comprehensive roadmap of cellular signaling.R35GM119536 · NIGMS · UNIVERSITY OF WASHINGTON · PI VILLEN, JUDIT · 2016 to 2020
$2.2M
The role of phosphorylation in the cellular organization of the proteomeR35GM152061 · NIGMS · UNIVERSITY OF WASHINGTON · PI Judit Villen · 2024 to 2026
$1.3M
CIHR 387697Danmarks Frie Forskningsfond (DFF) 0131-00031BEuropean Molecular Biology Organization (EMBO) ALTF 1069-2019European Molecular Biology Organization (EMBO) ALTF481-2020Human Frontier Science Program (HFSP) RGP34/2018NHGRI NIH HHS T32 HG000035NIA NIH HHS R01 AG056359NIGMS NIH HHS R35 GM119536NIGMS NIH HHS R35 GM152061NIH HHS R01AG056359NIH HHS R35GM119536NIH HHS R35GM152061NIH training grant T32HG000035Swiss National Science Foundation P5R5PB_211122
6 · The paper itself

Abstract

The fidelity of signal transduction requires the binding of regulatory molecules to their cognate targets. However, the crowded cell interior risks off-target interactions between proteins that are functionally unrelated. How such off-target interactions impact fitness is not generally known. Here, we use Saccharomyces cerevisiae to inducibly express tyrosine kinases. Because yeast lacks bona fide tyrosine kinases, the resulting tyrosine phosphorylation is biologically spurious. We engineered 44 yeast strains each expressing a tyrosine kinase, and quantitatively analysed their phosphoproteomes. This analysis resulted in ~30,000 phosphosites mapping to ~3500 proteins. The number of spurious pY sites generated correlates strongly with decreased growth, and we predict over 1000 pY events to be deleterious. However, we also find that many of the spurious pY sites have a negligible effect on fitness, possibly because of their low stoichiometry. This result is consistent with our evolutionary analyses demonstrating a lack of phosphotyrosine counter-selection in species with tyrosine kinases. Our results suggest that, alongside the risk for toxicity, the cell can tolerate a large degree of non-functional crosstalk as interaction networks evolve.

Indexed as

Saccharomyces cerevisiaeSaccharomyces cerevisiae ProteinsGenetic FitnessPhosphoproteinsPhosphorylationProtein-Tyrosine KinasesSignal TransductionPhosphoproteinsProtein-Tyrosine KinasesSaccharomyces cerevisiae ProteinsEvolutionGene EditingPhosphoproteomicsProtein KinasesStructural Bioinformatics

Identifiers

PMID39256561
PMCPMC11480408

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.